Prof. Dr. Monika Kirsch
Professorin für Angewandte Gesundheits- und Pflegewissenschaften
Fachliche Beratung zum Master-Studiengang Advanced Practice in Healthcare
Erzbergerstraße 121, Raum F372
- Telefon:
- +49.721.9735-857
- E-Mail:
- monika.kirsch @dhbw-karlsruhe.de
Wissenschaftliche Ausbildung
2010 ‑ 2014 |
Wissenschaftliche Mitarbeiterin und Promotion am Institut für Pflegewissenschaft, Universität Basel |
2006 ‑ 2009 |
Studium der Pflegewissenschaft am Institut für Pflegewissenschaft, Universität Basel |
Berufliche Tätigkeiten
seit Januar 2022 |
Professorin für Angewandte Gesundheits- und Pflegewissenschaften, DHBW Karlsruhe |
2021 |
Elternzeit |
2015 ‑ 2021 |
Pflegeexpertin, Advanced Practice Nurse (APN) Schmerztherapie Abteilung Schmerztherapie am Department für Anästhesiologie, Universitätsspital Basel |
2010 ‑ 2015 |
Pflegeexpertin (APN) Hämatologie Zellersatzambulatorium & Tagesklinik, Stammzelltransplantationszentrum, Universitätsspital Basel |
2005 ‑ 2010 |
Pflegefachfrau Innere Medizin/Onkologie und Isolierstation, Stammzelltransplantationszentrum, Universitätsspital Basel |
2003 ‑ 2004 |
Pflegefachfrau Chrischona Klinik, Bürgerspital Basel |
2000 ‑ 2003 |
Ausbildung zur examinierten Krankenschwester Krankenpflegeschule Kreiskrankenhaus Dormagen |
Lehrgebiete
- Pflegetheorie und Forschung
- Erweiterte Pflegepraxis
- Onkologische Pflege und Schmerztherapie
- Pflegeassessment und -diagnostik
Forschungsgebiete
- Patientenselbstmanagement
- Symptommanagement
- Praxisentwicklung in der Pflege
Veröffentlichungen
2021
-
(2021): Patient preferences for allogeneic haematopoietic stem cell transplantation: how much benefit is worthwhile from the patient's perspective?. In: Support Care Cancer 6 (Jun;29(6)), S. 3129-3135. DOI: 10.1007/s00520-020-05816-z
2020
-
(2020): Zusammenfassung von zwei Studien zur Validierung des Critical Care Pain Observation Tool (CPOT) zur Beurteilung von Schmerzen bei nichtäußerungsfähigen Intensivpatienten. In: Anaesthesist 7 (69), S. 487-488. DOI: 10.1007/s00101-020-00799-2
2019
2018
-
(2018): Symptom experience of multiple myeloma (syMMex) patients treated with autologous stem cell transplantation following high-dose melphalan: a descriptive longitudinal study. In: Supportive Care in Cancer 3 (26), S. 833-841. DOI: 10.1007/s00520-017-3897-z
-
(2018): Practice patterns to improve pre and post-transplant medication adherence in heart transplant centres: a secondary data analysis of the international BRIGHT study. In: European journal of cardiovascular nursing 17 (4), S. 356-367. DOI: 10.1177/1474515117747577
DOI: http://www.ncbi.nlm.nih.gov/pubmed/29231747 Abstract: BACKGROUND As medication non-adherence is a major risk factor for poor post-transplant outcomes, we explored how adherence is assessed, enhanced and integrated across the transplant continuum. AIM The aim of this study was to study practice patterns regarding pre- and post-transplant medication adherence assessment and interventions in international heart transplant centres. METHODS We used data from the Building Research Initiative Group: chronic illness management and adherence in heart transplantation (BRIGHT) study, a cross-sectional study conducted in 36 heart transplant centres in 11 countries. On a 27-item questionnaire, 100 clinicians (range one to five per centre) reported their practice patterns regarding adherence assessment and intervention strategies pre-transplant, immediately post-transplant, less than one year, and one or more year post-transplant. Educational/cognitive, counselling/behavioural and psychosocial/affective strategies were assessed. Clinicians' responses (intervention present vs. absent; or incongruence in reporting intervention) were aggregated at the centre level. RESULTS The adherence assessment method most commonly used along the transplant continuum was questioning patients (range 75-88.9%). Pre-transplant, all three categories of intervention strategy were applied. Providing reading materials (82.9%) or instructions (68.6%), involving family or support persons in education (91.4%), and establishing partnership (91.4%) were used most frequently. Post-transplant, strategies closely resembled those employed pre-transplant. Training patients (during recovery) and cueing were more often applied during hospitalisation (74.3%). After the first year post-transplant, except for motivational interviewing (25.7-28.6%), the number of strategies decreased. CONCLUSIONS Across the transplant continuum, diverse adherence interventions are implemented; however, post-transplant, the frequency of adherence interventions decreases. Therefore, increased investment is necessary in long-term adherence interventions.
2017
-
(2017): Lack of association between relationship status and clinical outcome in allogeneic stem cell transplantation-the Swiss Transplant Cohort Study. In: Bone marrow transplantation 52 (12), S. 1686-1688. DOI: 10.1038/bmt.2017.204
-
(2017): Medication nonadherence to immunosuppressants after adult allogeneic haematopoietic stem cell transplantation: a multicentre cross-sectional study. In: Bone marrow transplantation 52 (2), S. 304-306. DOI: 10.1038/bmt.2016.262
-
(2017): Perception of late effects among long-term survivors after haematopoietic stem cell transplantation. Descriptive analysis and validation of the Brief Illness Perception Questionnaire. A sub-study of the PROVIVO study. In: Eur J Oncol Nurs, S. 17-27. DOI: 10.1016/j.ejon.2017.01.003
2016
-
(2016): Correlates and Outcomes of Posttransplant Smoking in Solid Organ Transplant Recipients: A Systematic Literature Review and Meta-Analysis. In: Transplantation 100 (11), S. 2252-2263. DOI: 10.1097/tp.0000000000001335
DOI: http://www.ncbi.nlm.nih.gov/pubmed/27479162 Abstract: BACKGROUND Despite smoking being an absolute or relative contraindication for transplantation, about 11% to 40% of all patients continue or resume smoking posttransplant. This systematic review with meta-analysis investigated the correlates and outcomes associated with smoking after solid organ transplantation. METHODS We searched PubMed, EMBASE, CINAHL, and PsycINFO from inception until January 2016, using state-of-the art methodology. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were computed for correlates/outcomes investigated 5 times or more. RESULTS Seventy-three studies (43 in kidney, 17 in heart, 12 in liver, 1 in lung transplantation) investigated 95 correlates and 24 outcomes, of which 6 correlates and 4 outcomes could be included in the meta-analysis. The odds of smoking posttransplant were 1.33 times higher in men (95% CI, 1.12-1.57). Older individuals were significantly less likely to smoke (OR, 0.48; 95% CI, 0.38-0.62), as were patients with a higher body mass index (OR, 0.68; 95% CI, 0.52-0.89). Hypertension (OR, 1.16; 95% CI, 0.77-1.75), diabetes mellitus (OR, 0.52; 95% CI, 0.15-1.78), and having a history of cardiovascular disease (OR, 0.92; 95% CI, 0.77-1.09) were not significant correlates. Posttransplant smokers had higher odds of newly developed posttransplant cardiovascular disease (OR, 1.41; 95% CI, 1.02-1.95), nonskin malignancies (OR, 2.58; 95% CI, 1.26-5.29), a shorter patient survival time (OR, 0.59; 95% CI, 0.44-0.79), and higher odds of mortality (OR, 1.74; 95% CI, 1.21-2.48). CONCLUSIONS Posttransplant smoking is associated with poor outcomes. Our results might help clinicians to understand which patients are more likely to smoke posttransplant, guide interventional approaches, and provide recommendations for future research.